Table 2.
Variables | Period of diagnosis |
Totala |
P value of test for trend over time | ||
---|---|---|---|---|---|
Dec. 2009 or earlier (N = 128) N (%) |
Jan. 2010 to Dec. 2019 (N = 722) N (%) |
Jan. 2020 or later (N = 258) N (%) |
(N = 1119) N (%) |
||
Breast surgery | 0.041 | ||||
Mastectomy | 119(93.0) | 641(88.8) | 230(89.1) | 1000(89.1) | |
Partial mastectomy | 7(5.5) | 31(4.3) | 5(1.9) | 43(3.8) | |
No | 1(0.8) | 34(4.7) | 17(6.6) | 53(4.7) | |
Unknown | 1(0.8) | 16(2.2) | 6(2.3) | 23(2.1) | |
Axillary surgery | <0.001 | ||||
SLNB | 10(7.8) | 154(21.3) | 100(38.8) | 265(23.7) | |
ALND | 112(87.5) | 459(63.6) | 125(48.4) | 705(63.0) | |
No | 4(3.1) | 81(11.2) | 25(9.7) | 110(9.8) | |
Unknown | 2(1.6) | 28(3.9) | 8(3.1) | 39(3.5) | |
Radiotherapy | 0.520 | ||||
Yes | 25(19.5) | 178(24.7) | 60(23.3) | 264(23.6) | |
No | 60(46.9) | 424(58.7) | 174(67.4) | 658(58.8) | |
Unknown | 43(33.6) | 120(16.6) | 24(9.3) | 197(17.6) | |
Chemotherapy | 0.002 | ||||
Yes | 71(55.5) | 376(52.1) | 136(52.7) | 588(52.5) | |
No | 17(13.3) | 234(32.4) | 89(34.5) | 339(30.3) | |
Unknown | 40(31.3) | 112(15.5) | 33(12.8) | 192(17.2) | |
Endocrine therapy (HR positive cases) | 0.165 | ||||
Yes | 89(78.1) | 458(72.2) | 168(71.5) | 716(72.3) | |
No | 9(7.9) | 92(14.5) | 32(13.6) | 133(13.4) | |
Unknown | 16(14.0) | 84(13.2) | 35(14.9) | 142(14.3) | |
Total | 114(100) | 634(100) | 235(100) | 991(100) | |
Anti-HER-2 therapy (HER-2 positive cases) | 0.010 | ||||
Yes | 1(14.3) | 33(40.2) | 32(72.7) | 63(47.0) | |
No | 1(14.3) | 30(36.6) | 7(15.9) | 40(29.9) | |
Unknown | 5(71.4) | 19(23.2) | 5(11.4) | 31(23.1) | |
Total | 7(100) | 82(100) | 44(100) | 134(100) |
Abbreviations: SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection; HR, hormone receptor; HER-2, human epidermal growth factor receptor 2.
The exact year of diagnosis of 11 cases were unknown. These cases were thus recorded in the column Total only.